FDA Grants Breakthrough Designation to Synapse Biomedical’s TransAeris® System

Synapse Biomedical, Inc®. announced today that the FDA has granted Breakthrough Therapy Device designation to TransAeris®, a temporary percutaneous intramuscular diaphragm stimulator designed to aid in weaning from mechanical ventilation.

TransAeris system is a temporary percutaneous intramuscular diaphragm stimulator intended for patients identified with a risk of prolonged mechanical ventilation: undergoing high-risk open cardiac surgery, lung transplant, thoracoabdominal aortic aneurysm surgical procedures or in patients that have already failed to wean and have been on mechanical ventilation for 96 or more hours, to prevent or treat ventilator induced diaphragm dysfunction (VIDD). Diaphragm Pacing may enhance recovery after surgery in patients at risk or on prolonged mechanical ventilation.

The FDA’s Breakthrough Therapy Device Program creates a path for innovators to get their medical devices to market faster. The program targets novel devices that have the potential to provide patients with a more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases and conditions. This program provides patients and health care providers with timely access to these medical devices by expediting medical devices development, assessment, and review, while preserving the statutory standards consistent with the FDA’s mission to protect and promote public health.

“The Breakthrough Device designation for our TransAeris temporary diaphragm stimulation system is built upon our 20-year experience with NeuRx diaphragm pacing,” said Anthony Ignagni, President & CEO.  “We have seen increasing early use of our NeuRx device in spinal cord injured patients and, coupled with the use of our TransAeris system over this past year intended to help ICU patients get off mechanical ventilation earlier under the Emergency Use Authorization program, we hope the mounting evidence and this designation along with our ongoing clinical studies will help move the TransAeris device along the path for quicker approval.”

TransAeris builds on the success of another Synapse Biomedical technology, the NeuRx® Diaphragm Pacing Stimulation (NeuRx DPS) System, which has been FDA and CE Mark approved since 2008 for people with Spinal Cord Injury (SCI) and has successfully reduced or eliminated the need for mechanical ventilation. TransAeris was created to assist patients with prolonged mechanical ventilation on a temporary basis up to 30 days, simplifying the external features of the NeuRx DPS system and distilling them into a single patient, 30-day use, disposable device. Since receiving CE mark in Europe for TransAeris, several centers in Europe and the Middle East, including BGU Murnau (Germany), have also used TransAeris successfully in acute spinal cord injury and polytrauma patients.

Hot this week

Avery Dennison Medical Introduces Ipdated SilFoam Lite: Sustainability, MDR Certification & Performance Improvements

The newly enhanced SilFoam Lite delivers superior efficiency and reliability, bringing improved fluid handling capabilities and improved tack. These improvements make the product ideal for customers seeking quality, high-performance solutions in wound care notes Avery Dennison Medical.

Voluntary Recall Notifying Medtronic Insulin Pump Users of Potential Risks of Shortened Pump Battery Life

Medtronic plc voluntarily issued a field action starting on July 31, 2024, notifying global customers of its MiniMed™ 600 series or 700 series insulin pumps to follow their pump's built-in alerts and alarms for battery status and to contact Medtronic if they observe changes in the battery life of their pump

Medtronic Expands AiBLE Spine Surgery Ecosystem with New Technologies and Siemens Healthineers Partnership

New advancements in the AiBLE Spine Surgery ecosystem build upon the company's commitment to procedural innovation and execution

Axlab, Danish Medtech Pioneer, expands to US with Advanced Robotic Tissue Sectioning for Pathology Laboratories

Kris Rokke, National Sales Director for Axlab in the US. "My team and I are extremely excited and honored about this unique opportunity to also offer this advanced technology to labs across the US and thus contribute to the pathology labs of tomorrow."

Spartan Medical Broadens Single-Use Sterile Instrument Portfolio to Improve Outcomes, Increase Efficiency, and Generate Cost Savings

Spartan Medical products portfolio of single-use, sterile med tech includes micro and minor surgical convenience kits, kerrison rongeurs, spinal and general surgical retractors, dural repair kits, synthetic biologics, and a wide range of orthopedic pre-sterilized implants and devices.